Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas B Johnson

Showing results (1-10 of 375) with videos related to

Pageof 38
Sort By:
Cancer|July 6, 2018
Toxicities and outcomes: Do steroids matter?Douglas B Johnson
Journal for Immunotherapy of Cancer|July 4, 2024
Chronic immune-related adverse events arising from immune checkpoint inhibitors: an updateKylie Fletcher, Douglas B Johnson
Expert Opinion on Drug Safety|August 30, 2023
Immune checkpoint inhibitor-related myocarditis: current understanding and potential diagnostic and therapeutic strategiesIsik Turker, Douglas B Johnson
Current Treatment Options in Oncology|September 20, 2022
Antibody-Drug Conjugates for Melanoma and Other Skin MalignanciesRachel Goodman, Douglas B Johnson
The Oncologist|May 31, 2022
Management of Acral and Mucosal Melanoma: Medical Oncology PerspectiveSeungyeon Jung, Douglas B Johnson
Journal for Immunotherapy of Cancer|November 16, 2019
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitorsSatya Das, Douglas B Johnson
Current Treatment Options in Oncology|March 23, 2015
Treatment of NRAS-mutant melanomaDouglas B Johnson, Igor Puzanov
Expert Review of Anticancer Therapy|December 10, 2025
Overcoming toxicity challenges in immune checkpoint inhibitor treatment of high-risk metastatic cancersRishitha Nalabothu, Douglas B Johnson
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2014
BRAFV600E-mutant melanoma presenting with cardiac involvementDouglas B Johnson, Jeffrey A Sosman
The Oncologist|January 20, 2025
Steroid-refractory immune mediated hepatitis managed with budesonide in patients with metastatic melanoma: proof of concept and literature reviewRoma A Kankaria, Douglas B Johnson
Pageof 38

Showing results (1-10 of 375) with videos related to

Sort By:
Pageof 38
Cancer|July 6, 2018
Toxicities and outcomes: Do steroids matter?Douglas B Johnson
Journal for Immunotherapy of Cancer|July 4, 2024
Chronic immune-related adverse events arising from immune checkpoint inhibitors: an updateKylie Fletcher, Douglas B Johnson
Expert Opinion on Drug Safety|August 30, 2023
Immune checkpoint inhibitor-related myocarditis: current understanding and potential diagnostic and therapeutic strategiesIsik Turker, Douglas B Johnson
Current Treatment Options in Oncology|September 20, 2022
Antibody-Drug Conjugates for Melanoma and Other Skin MalignanciesRachel Goodman, Douglas B Johnson
The Oncologist|May 31, 2022
Management of Acral and Mucosal Melanoma: Medical Oncology PerspectiveSeungyeon Jung, Douglas B Johnson
Journal for Immunotherapy of Cancer|November 16, 2019
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitorsSatya Das, Douglas B Johnson
Current Treatment Options in Oncology|March 23, 2015
Treatment of NRAS-mutant melanomaDouglas B Johnson, Igor Puzanov
Expert Review of Anticancer Therapy|December 10, 2025
Overcoming toxicity challenges in immune checkpoint inhibitor treatment of high-risk metastatic cancersRishitha Nalabothu, Douglas B Johnson
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2014
BRAFV600E-mutant melanoma presenting with cardiac involvementDouglas B Johnson, Jeffrey A Sosman
The Oncologist|January 20, 2025
Steroid-refractory immune mediated hepatitis managed with budesonide in patients with metastatic melanoma: proof of concept and literature reviewRoma A Kankaria, Douglas B Johnson
Pageof 38